A profitable, high-margin “razor-and-blade” bladder-cancer franchise with two major upside catalysts: U.S. regulatory unlock for hardware and a potentially transformative China royalty stream from Cevira.
Overview
Photocure ASA is a focused uro-oncology company monetizing photodynamic “blue light” technology to improve bladder cancer detection. Its flagship product, Hexvix (Cysview in North America), is a photosensitizing drug used with blue light cystoscopy hardware to detect NMIBC more effectively than white light, particularly for hard-to-see CIS lesions. The investment case centers on a transition from capital-intensive expansion to operating leverage: Photocure combines direct commercialization in North America and core Europe (selling both consumables and enabling system placement) with licensing elsewhere to generate high-margin royalties. A key hidden asset is Cevira (APL-1702), licensed to Asieris and under China NMPA review; approval could unlock up to $250M in milestones and double-digit royalties that are largely uncorrelated with the bladder franchise. Operationally, the company is rebuilding U.S. surveillance exposure after Karl Storz’ flexible-scope withdrawal by deploying ForTec’s mobile model and partnering with Richard Wolf (and engaging Olympus) for new hardware pathways, while also supporting a pivotal FDA petition to reclassify BLC devices from Class III to Class II. Financially, Photocure delivered 10% revenue growth in 2024 with positive EBITDA, and by Q3 2025 showed continued double-digit growth (12% YoY), expanding EBITDA, and a debt-light balance sheet with ~NOK 248M cash. The convergence of improving fundamentals and multiple catalysts (FDA decision, flexible scope rollout, China approval) places the company at an inflection point.